Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-adjusted Indirect Comparison
The above plain language summary represents the opinions of
the authors. For a full list of declarations, including
funding and author disclosure statements, please see the full text online (see
“read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.